-
NEWS: England faces £1.2 billion in healthcare costs if Covid-19 lockdown alcohol consumption trends persist to 2035
When the Covid-19 pandemic hit in early 2020, drinking habits shifted significantly for many. But what happens when those pandemic-era drinking habits stick around? Recent research from HealthLumen explores the long-term consequences of changes in alcohol consumption during the pandemic, and the findings are stark: if those patterns continue until the end of 2035, England could face nearly 10,000 additional premature deaths, over 147,000 excess cases of disease, and £1.2 billion extra in healthcare costs.
-
Demonstrating the value of cascade screening using microsimulation modelling: A pathway to faster diagnosis and improved patient outcomes for genetic diseases
Earlier diagnosis can make all the difference for individuals with genetic diseases. Delayed diagnosis hinders timely disease management and treatment access, meaning that progression to late-stage disease can occur more rapidly, likely leading to a significant increase in the health and economic burden of these conditions for patients, their families, and healthcare systems. Screening programs aim to identify individuals with genetic conditions earlier, with cascade screening in particular providing one way to help transform outcomes for patients.
-
The Inside CKD online hub: Turning research into policy action
As part of AstraZeneca’s Accelerate Change Together (ACT) on CKD programme to drive chronic kidney disease (CKD) change across the healthcare ecosystem, the Inside CKD project stream projected the clinical and economic burden of CKD from 2022 to 2027 across 31 countries and regions. The results have recently been compiled into a comprehensive portal on the Inside CKD website.
-
NEWS: HealthLumen launches AlleleAtlas, a tool for estimating the prevalence of rare genetic diseases
HealthLumen has today announced the launch of AlleleAtlas, the genetic variant prevalence projection tool. The tool has been developed to bring a valuable resource to the rare disease community, including those engaged in rare disease research and therapeutics in the pharmaceutical, biotech and research spaces, and for patient advocacy organisations aiming to raise awareness.
-
World Diabetes Day 2024: A holistic approach to tackling diabetes
November 14th marks World Diabetes Day, a powerful opportunity to raise awareness of diabetes as a major global health issue. This year’s theme, “Breaking Barriers, Bridging Gaps”, calls for action to reduce diabetes risk factors and ensure equitable access to quality treatment worldwide [1]. The global diabetes crisis: A growing challenge Diabetes currently impacts over […]
-
HealthLumen modelling study for Nesta identifies the government interventions needed to halve obesity in the UK over five years
Study highlights which health policies are most likely to be effective in decreasing the prevalence of obesity, with fiscal policies expected to be particularly cost beneficial. This research has informed Nesta’s digital Blueprint tool – which provides data on the health, economic, and feasibility impacts of various obesity interventions – aligning with Nesta’s mission of halving obesity rates in the UK by 2030.
-
Join HealthLumen at key upcoming rare disease conferences in Q4 2024
HealthLumen are looking forward to discussing our work on the prevalence of rare diseases and engaging with colleagues dedicated to accelerating rare disease therapeutics at several upcoming conferences in the final quarter of this year.
-
NEWS: New research identifying the number of women at risk of FNAIT to be presented at ASHG 2024
Rallybio, a clinical-stage biotechnology company, will be presenting the findings of a genetic database analysis study conducted in partnership with HealthLumen on Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) risk across racially and ethnically diverse populations at the American Society of Human Genetics (ASHG) 2024 Annual Meeting. The conference will take place from November 5–9 2024 in Denver, Colorado.
-
Genomics and precision medicine: The new frontier for microsimulation
“Genomics requires a form of modelling that can capture individual genetic differences and responses to therapy – a purpose to which microsimulation is eminently suited.”
This quote, from a seminal review paper by Professors Deborah Schofield and Rupendra Shrestha of Macquarie University, pioneers in applying microsimulation techniques for modelling the costs and benefits of genomic medicine, formed the basis for a fascinating recent discussion with the HealthLumen team, on the role of microsimulation modelling techniques in precision medicine.
-
Investing in prevention for men’s health: Increasing NHS Health Check attendance could save the NHS billions
HealthLumen was recently commissioned by Movember, one of the leading charities changing the face of men’s health, to quantify the economic impact of men’s poor health for their ‘Real Face of Men’s Health’ 2024 UK Report. The study found that in 2023 the five diseases that cause the largest number of years of life lost […]
